ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GOSS Gossamer Bio Inc

0.7651
-0.0409 (-5.07%)
Apr 19 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 668,635
Bid Price 0.765
Ask Price 0.85
News -
Day High 0.8499

Low
0.4525

52 Week Range

High
1.88

Day Low 0.769
Company Name Stock Ticker Symbol Market Type
Gossamer Bio Inc GOSS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0409 -5.07% 0.7651 19:54:52
Open Price Low Price High Price Close Price Prev Close
0.80 0.769 0.8499 0.7838 0.806
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,122 668,635 $ 0.7930911 $ 530,288 - 0.4525 - 1.88
Last Trade Time Type Quantity Stock Price Currency
19:54:52 formt 209 $ 0.7651 USD

Gossamer Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
175.95M 225.58M - 0 -179.82M -0.80 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Gossamer Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GOSS Message Board. Create One! See More Posts on GOSS Message Board See More Message Board Posts

Historical GOSS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.95340.99370.7690.8470617948,240-0.1883-19.75%
1 Month1.351.400.7691.071,511,269-0.5849-43.33%
3 Months0.811.600.761.181,361,428-0.0449-5.54%
6 Months0.631.600.45250.92498781,600,8370.135121.44%
1 Year0.96241.880.45251.071,887,679-0.1973-20.50%
3 Years8.4715.1950.45253.861,783,200-7.70-90.97%
5 Years16.5627.14970.45255.531,290,493-15.79-95.38%

Gossamer Bio Description

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Your Recent History

Delayed Upgrade Clock